Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael B Atkins

Showing results (1-10 of 338) with videos related to

Pageof 34
Sort By:
Clinical Advances in Hematology & Oncology : H&O|August 2, 2023
Update on the DREAMseq trial in melanomaMichael B Atkins
Kidney International|April 21, 2005
Management of advanced renal cancerMichael B Atkins
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Cytokine-based therapy and biochemotherapy for advanced melanomaMichael B Atkins
Medical Oncology (Northwood, London, England)|January 24, 2009
Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapyMichael B Atkins
Clinical Advances in Hematology & Oncology : H&O|July 4, 2007
The effect of recent drug approvals on translational research and drug developmentMichael B Atkins
Seminars in Oncology|June 18, 2002
Interleukin-2: clinical applicationsMichael B Atkins
Clinical Advances in Hematology & Oncology : H&O|July 6, 2016
What is optimal first-line treatment of unresectable or advanced BRAF-mutant melanoma?Michael B Atkins
Cancer Journal (Sudbury, Mass.)|May 28, 2013
Is interleukin 2 the best initial therapy for many patients with metastatic renal cell carcinoma?George Philips, Michael B Atkins
The Lancet. Oncology|February 2, 2013
Which drug, and when, for patients with BRAF-mutant melanoma?Sekwon Jang, Michael B Atkins
Seminars in Oncology|August 31, 2015
Cancer Immunotherapy: Past Progress and Future DirectionsMichael B Atkins, Mario Sznol
Pageof 34

Showing results (1-10 of 338) with videos related to

Sort By:
Pageof 34
Clinical Advances in Hematology & Oncology : H&O|August 2, 2023
Update on the DREAMseq trial in melanomaMichael B Atkins
Kidney International|April 21, 2005
Management of advanced renal cancerMichael B Atkins
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Cytokine-based therapy and biochemotherapy for advanced melanomaMichael B Atkins
Medical Oncology (Northwood, London, England)|January 24, 2009
Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapyMichael B Atkins
Clinical Advances in Hematology & Oncology : H&O|July 4, 2007
The effect of recent drug approvals on translational research and drug developmentMichael B Atkins
Seminars in Oncology|June 18, 2002
Interleukin-2: clinical applicationsMichael B Atkins
Clinical Advances in Hematology & Oncology : H&O|July 6, 2016
What is optimal first-line treatment of unresectable or advanced BRAF-mutant melanoma?Michael B Atkins
Cancer Journal (Sudbury, Mass.)|May 28, 2013
Is interleukin 2 the best initial therapy for many patients with metastatic renal cell carcinoma?George Philips, Michael B Atkins
The Lancet. Oncology|February 2, 2013
Which drug, and when, for patients with BRAF-mutant melanoma?Sekwon Jang, Michael B Atkins
Seminars in Oncology|August 31, 2015
Cancer Immunotherapy: Past Progress and Future DirectionsMichael B Atkins, Mario Sznol
Pageof 34